Kosin Med J.  2025 Mar;40(1):49-54. 10.7180/kmj.24.145.

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab

• Bae SH
• Kim BJ
• Kim SJ
• Im SI
• Kim HS
• Heo JH

• KMID: 2566131
• DOI: http://doi.org/10.7180/kmj.24.145

Abstract

Background
The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and alirocumab has not been fully established. This study evaluated the lipid-lowering effects of these two PCSK9 inhibitors.
Methods
Patients diagnosed with ACS, including unstable angina, ST-segment elevation myocardial infarction, and non-ST-segment elevation myocardial infarction, who were treated with a PCSK9 inhibitor (evolocumab or alirocumab) during hospitalization for ACS between 2021 and 2023 were retrospectively analyzed. Baseline low-density lipoprotein cholesterol (LDL-C) levels were assessed, and changes in LDL-C levels during the acute and subacute phases after PCSK9 inhibitor administration were compared between the evolocumab and alirocumab groups.
Results
Among 80 patients diagnosed with ACS, 36 received evolocumab, while 44 were treated with alirocumab. The mean baseline LDL-C level was 123 mg/dL in the evolocumab group and 128 mg/dL in the alirocumab group (p=0.456). In the subacute phase, the mean follow-up LDL-C levels were 47.05 mg/dL in the evolocumab group and 49.5 mg/dL in the alirocumab group (p=0.585). The mean percentage reduction in LDL-C levels during the subacute phase was 60.41% in the evolocumab group and 58.51% in the alirocumab group (p=0.431). These differences were not statistically significant.
Conclusions
No significant differences were observed between evolocumab and alirocumab. LDL-C levels exhibited a similar trend, characterized by a rapid decline in the acute phase, followed by a slight rebound in the subacute phase.

Keyword

Acute coronary syndrome; Alirocumab; Evolocumab; LDL cholesterol

Figure

• 

  Fig. 1. Trends in low-density lipoprotein cholesterol (LDL-C) levels over time in the (A) evolocumab and (B) alirocumab groups.

Reference

References

1. Committee of Clinical Practice Guideline of the Korean Society of Lipid and Atherosclerosis. Korean Guidelines for the Management of Dyslipidemia 5th [Internet]. The Korean Society of Lipid and Atherosclerosis;2022. [cited 2025 Mar 24]. https://www.lipid.or.kr/eng/pub/images/guidlines_2022.pdf.

2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376:1713–22. DOI: 10.1056/nejmoa1615664. PMID: 28304224.

3. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379:2097–107. DOI: 10.1056/nejmoa1801174. PMID: 30403574.

4. Mehta SR, Pare G, Lonn EM, Jolly SS, Natarajan MK, Pinilla-Echeverri N, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022; 18:e888–96. DOI: 10.4244/eij-d-22-00735. PMID: 36349701.

5. Choi SW, Kim J, Jang GW, Lee YS, Park JS, Lee JM, et al. Acute effect of evolocumab on lipoprotein(a) level and inflammation in patients with coronary artery disease. J Cardiovasc Dev Dis. 2022; 9:101. DOI: 10.3390/jcdd9040101. PMID: 35448076.

6. Guedeney P, Sorrentino S, Giustino G, Chapelle C, Laporte S, Claessen BE, et al. Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2021; 7:225–35. DOI: 10.1093/ehjcvp/pvaa024. PMID: 32275743.

7. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Reprint of: Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018; 72(23 Pt B):2980–95. DOI: 10.1016/j.jacc.2018.10.021. PMID: 30522632.

8. Lombardo A, Biasucci LM, Lanza GA, Coli S, Silvestri P, Cianflone D, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation. 2004; 109:3158–63. DOI: 10.1161/01.cir.0000130786.28008.56. PMID: 15184282.